Germline mutations in high penetrance genes are associated with worse clinical outcomes in patients with non–small cell lung cancerCentral MessagePerspective by Seth B. Krantz, MD, Kanwal Zeeshan, MBBS, Kristine M. Kuchta, MS, Thomas A. Hensing, MD, Kathy A. Mangold, PhD, S. Lilly Zheng, MD, Jianfeng Xu, MD, DrPH

Get full text

Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastati... by Thomas A. Hensing, MD, MS, Xiaofei Wang, PhD, Thomas E. Stinchcombe, MD, Junheng Gao, MS, Michael V. Knopp, MD, PhD, Mark Watson, MD, PhD, Arkadiusz Z. Dudek, MD, PhD, Stephen L. Graziano, MD, Jyoti D. Patel, MD, Bryan A. Faller, MD, Konstantin H. Dragnev, MD, David Kozono, MD, PhD, Everett E. Vokes, MD

Get full text